BMO's Evan Seigerman joins 'Power Lunch' to talk about what he is looking for when it comes to the upcoming slate of ...

Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two ...

Two of the world's biggest pharmaceutical companies are headed to court after Novo Nordisk, the maker of Ozempic and a ...

Novo Nordisk and Eli Lilly produce GLP-1s across their respective North Carolina facilities near Raleigh and Charlotte.

There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of ...

Eli Lilly said Thursday it plans to file for regulatory approval of its next-generation weight loss drug retatrutide in the ...

Eli Lilly will seek regulatory approval for retatrutide, a powerful weight loss drug that a new study shows helped people lose nearly 56 pounds on average.

Eli Lilly & Co.’s highly anticipated next-generation weight-loss shot didn’t increase overall heart risk in a new study, the ...

Armed with new pivotal trial results, Eli Lilly plans to file for approval of its keenly anticipated new weight-loss therapy, ...

Eli Lilly said Thursday it will delay filing for FDA approval of its next-gen weight-loss drug, retatrutide, until the first quarter.

Novo Nordisk just sued Eli Lilly over weight-loss drug ads, but the moment the lawsuit hit, investors moved in exactly the ...

Eli Lilly’s triple-G drug retatrutide has hit the primary endpoints of a pair of phase 3 obesity trials, although the peak ...